The role of meta-analyses in assessing cancer treatments (Q33971420)

30 July 2017

1 reference

title

The role of meta-analyses in assessing cancer treatments (English)

1 reference

30 July 2017

0 references

Sylvester R

1

1 reference

PubMed ID

10899647

30 July 2017

Collette L

series ordinal

2

1 reference

PubMed ID

10899647

30 July 2017

Duchateau L

series ordinal

3

1 reference

30 July 2017

1 July 2000

1 reference

European Journal of Cancer

30 July 2017

1 reference

30 July 2017

36

1 reference

30 July 2017

11

1 reference

30 July 2017

1351-1358

1 reference

Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Individual patient data meta-analysis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get!

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Publication Bias: A Problem in Interpreting Medical Data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Statistics in medical journals: Developments in the 1980s

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Publication bias: the case for an international registry of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis: reconciling the results of independent studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Intention to treat--who should use ITT?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis and meta-analytic monitoring of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

A note on graphical presentation of estimated odds ratios from several clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Evidence-based cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Disturbed by Meta-Analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis: science or religion?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Misleading meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis and its problems

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Overcoming the limitations of current meta-analysis of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

Meta-analysis: weighing the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900125-8

7 January 2021

10.1016/S0959-8049(00)00125-8

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10899647